NASDAQ:PLRX Pliant Therapeutics Q2 2026 Earnings Report $1.08 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pliant Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.34Beat/MissMissed by -$0.02One Year Ago EPSN/APliant Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APliant Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time7:00AM ETUpcoming EarningsPliant Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pliant Therapeutics Earnings HeadlinesPliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street ZenSeptember 26 at 1:24 AM | americanbankingnews.comPliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from S&P Global BMI IndexSeptember 21, 2026 | marketscreener.comMDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade. Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires. | Profits Run (Ad)Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $3.00 Average Target Price from AnalystsSeptember 17, 2026 | americanbankingnews.comPliant Therapeutics consensus price target lowered 20% to $2.04September 16, 2026 | msn.comPliant Therapeutics Inc Ordinary Shares PLRXAugust 28, 2026 | morningstar.comMSee More Pliant Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email. Email Address About Pliant TherapeuticsPliant Therapeutics (NASDAQ:PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research centers on integrins, cell-surface proteins that regulate biological processes involved in tissue repair and fibrosis. Pliant seeks to develop medicines that address fibrosis in organs including the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral small-molecule inhibitor designed to selectively target the alphaV beta6 and alphaV beta1 integrins. The therapy has been evaluated in clinical studies for idiopathic pulmonary fibrosis and is also being investigated for liver-related fibrotic diseases, including primary sclerosing cholangitis. As an investigational medicine, bexotegrast has not been approved for commercial use. Founded in 2015 and headquartered in South San Francisco, California, Pliant conducts research and clinical development primarily in the United States while working with clinical and research partners in other regions as its programs advance. The company is led by Chief Executive Officer Bernard Coulie, M.D., Ph.D., and its shares trade on the Nasdaq under the symbol PLRX.View Pliant Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
